Neurocrine Biosciences, Inc. Share Price London S.E.
Equities
0K6R
US64125C1099
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
138.9 USD | -0.37% | +2.22% | +4.83% |
Sales 2024 * | 2.22B 174B | Sales 2025 * | 2.55B 201B | Capitalization | 13.39B 1,053B |
---|---|---|---|---|---|
Net income 2024 * | 431M 33.88B | Net income 2025 * | 675M 53.07B | EV / Sales 2024 * | 5.13 x |
Net cash position 2024 * | 2B 157B | Net cash position 2025 * | 2.81B 221B | EV / Sales 2025 * | 4.15 x |
P/E ratio 2024 * |
32.8
x | P/E ratio 2025 * |
21
x | Employees | 1,448 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.2% |
Latest transcript on Neurocrine Biosciences, Inc.
1 day | -0.37% | ||
1 week | +2.22% | ||
Current month | +3.16% | ||
1 month | -2.58% | ||
3 months | +5.14% | ||
6 months | +16.04% | ||
Current year | +4.83% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 31/12/91 |
Director of Finance/CFO | 44 | 31/10/17 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 29/11/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 31/03/99 |
George Morrow
BRD | Director/Board Member | 72 | 30/09/15 |
Kevin Gorman
FOU | Founder | 66 | 31/12/91 |
Date | Price | Change | Volume |
---|---|---|---|
07/06/24 | 135.6 | +2.90% | 105 |
06/06/24 | 131.8 | -2.44% | 328 |
05/06/24 | 135.1 | -0.60% | 300 |
04/06/24 | 135.9 | -2.40% | 73 |
03/06/24 | 139.3 | +3.42% | 245 |
Delayed Quote London S.E., May 22, 2024 at 02:31 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-13.31% | 16.5B | |
+27.89% | 11.1B | |
+83.45% | 9.22B |
- Stock Market
- Equities
- NBIX Stock
- 0K6R Stock